Enpatoran clinical trials
Enpatoran is named as an intervention in 4 current clinical trials in our USA, China, Germany, Spain, Poland, Brazil, South Korea, Taiwan, Australia, Israel, UK, Italy, Belgium, Switzerland, Japan, France, Czechia, Canada and Mexico registers. 2 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is EMD Serono Research & Development Institute, Inc (3). The most-studied condition is Systemic Lupus Erythematosus (SLE).
How Enpatoran works
All drug targets →- Toll-like receptor 8 antagonist AntagonistTarget: TLR8 toll like receptor 8ChEMBL only
- Toll-like receptor 7 antagonist AntagonistTarget: TLR7 toll like receptor 7✓ In ChEMBL and the Guide to Pharmacology
- Lupus erythematosusPhase 3
- Cutaneous lupus erythematosusPhase 2
- DermatomyositisPhase 2
- Discoid lupus erythematosusPhase 2
- PolymyositisPhase 2
- Systemic lupus erythematosusPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4802159, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 11307, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Enpatoran
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Enpatoran
4 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Enpatoran
5 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| EMD Serono Research & Development Institute, Inc | 3 |
| Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Enpatoran trials
How many clinical trials are testing Enpatoran?
4 current trials in our USA, China, Germany, Spain, Poland, Brazil, South Korea, Taiwan, Australia, Israel, UK, Italy, Belgium, Switzerland, Japan, France, Czechia, Canada and Mexico registers name Enpatoran (also registered as M5049) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Enpatoran trials recruiting patients?
Yes. 2 of the 4 trials are recruiting: 2 with sites in USA, 2 with sites in China, 2 with sites in Germany, 2 with sites in Spain, 2 with sites in Poland, 2 with sites in Brazil, 2 with sites in South Korea, 2 with sites in Taiwan, 2 with sites in Australia, 2 with sites in Israel, 2 with sites in UK, 2 with sites in Italy, 2 with sites in Belgium, 2 with sites in Switzerland, 1 with sites in Japan, 1 with sites in France, 1 with sites in Czechia and 1 with sites in Canada. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Enpatoran clinical trials?
EMD Serono Research & Development Institute, Inc (3) and Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Enpatoran works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Enpatoran works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Enpatoran (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.